PMID- 38357230
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240216
IS  - 2049-9442 (Electronic)
IS  - 2049-9434 (Print)
IS  - 2049-9434 (Linking)
VI  - 20
IP  - 3
DP  - 2024 Mar
TI  - Reactive cutaneous capillary endothelial proliferations of the eyelids induced by 
      camrelizumab: A case report.
PG  - 53
LID - 10.3892/br.2024.1743 [doi]
LID - 53
AB  - With the widespread application of immune checkpoint inhibitors, a series of 
      adverse events (AEs) related to treatment resulting from alterations in the 
      immune system have emerged that warrant attention. The present study report the 
      case of a patient with reactive cutaneous capillary endothelial proliferations 
      (RCCEPs) on the eye lid, following treatment with the programmed cell death 
      protein 1 inhibitor camrelizumab (SHR-1210) for stage IIa2 well- to moderately 
      differentiated squamous cell carcinoma of the cervix. Although RCCEPs have been 
      revealed to be the most common AEs of SHR-1210, they are usually distributed on 
      the head, neck, trunk and extremities. The current study presents a rare case of 
      ocular RCCEPs induced by SHR-1210. Prompt diagnosis and treatment of 
      immune-related AEs is crucial for the optimal management of patients. Although 
      RCCEPs are usually slight-risk toxicities that pose no threat to the continuity 
      of treatment, lesions with unusual distributions that cause disturbances in 
      normal life require proper treatment, such as surgical excision.
CI  - Copyright: (c) Zhou et al.
FAU - Zhou, Xuecong
AU  - Zhou X
AD  - Department of Ophthalmology, Peking University First Hospital, Peking University, 
      Beijing 100034, P.R. China.
FAU - Yan, Xiaoming
AU  - Yan X
AD  - Department of Ophthalmology, Peking University First Hospital, Peking University, 
      Beijing 100034, P.R. China.
FAU - Wu, Yuan
AU  - Wu Y
AD  - Department of Ophthalmology, Peking University First Hospital, Peking University, 
      Beijing 100034, P.R. China.
LA  - eng
PT  - Case Reports
DEP - 20240201
PL  - England
TA  - Biomed Rep
JT  - Biomedical reports
JID - 101613227
PMC - PMC10865177
OTO - NOTNLM
OT  - camrelizumab
OT  - immune checkpoint inhibitors
OT  - immune-related adverse events
OT  - programmed cell death protein 1
OT  - reactive cutaneous capillary endothelial proliferations
COIS- The authors declare that they have no competing interests.
EDAT- 2024/02/15 06:42
MHDA- 2024/02/15 06:43
PMCR- 2024/02/01
CRDT- 2024/02/15 04:18
PHST- 2023/10/10 00:00 [received]
PHST- 2024/01/05 00:00 [accepted]
PHST- 2024/02/15 06:43 [medline]
PHST- 2024/02/15 06:42 [pubmed]
PHST- 2024/02/15 04:18 [entrez]
PHST- 2024/02/01 00:00 [pmc-release]
AID - BR-20-3-01743 [pii]
AID - 10.3892/br.2024.1743 [doi]
PST - epublish
SO  - Biomed Rep. 2024 Feb 1;20(3):53. doi: 10.3892/br.2024.1743. eCollection 2024 Mar.